Management of NSAID-induced ulcer disease.
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of gastric and duodenal ulcers, especially in patients with previous ulcer disease, heavy smokers, patients who are taking steroids and those with other illnesses. In patients at risk for gastroduodenal complications, prophylactic therapy with misoprostol or an H2-receptor antagonist should be considered. If ulcers occur during NSAID therapy, the anti-inflammatory drug should be discontinued and standard ulcer-healing therapy instituted. If NSAID therapy must be continued, ulcer healing may be prolonged.
Clearfield
H R
HR
Krancer Center for Inflammatory Bowel Disease Research, Hahnemann University Philadelphia, Pennsylvania.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002985:Clinical Protocols; D005194:Family Practice / Q000379:methods*; D006801:Humans; D010437:Peptic Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents